Clinical Trial News Archive
Get news by email or subscribe to our news feeds.
News Archive for October 2009
October 1, 2009
- FDA Issues Draft Guidance on Risk Evaluation and Mitigation Strategies
- Halozyme Presents Phase 2 Results for Regular Insulin-PH20 Confirming Faster Insulin Absorption and Superior Glucose Control
- Bristol-Myers Squibb and ZymoGenetics to Present Final Phase Ib Data on PEG-Interferon Lambda at AASLD 2009
- WILEX AG: Preliminary data of MESUPRON show impressive increase in overall survival of patients with pancreatic cancer
- XOMA Presents Results Demonstrating Novel Mechanism of Action for XOMA 052 in Regulating IL-1 Beta Levels
- Study Shows AFRESA Provides Rapid Suppression of Endogenous Glucose Production in Diabetes Patients
- Scientists Report Impressive Research Results with Tβ4 on First Day of Thymosin Meeting
- Positive Interim Data from Minnow Medical Peripheral Artery Disease Trial Presented at TCT 2009 Conference
- BreastCancerTrials.org and Largest Breast Cancer Trial Announced
- Drug That Crosses Blood-Brain Barrier Reduces Formation Of Brain Metastases In Mice
- Telik Announces Publication of Positive Phase 1-2a Results of a Multicenter Study of TELCYTA(R) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer
- Sanofi Pasteur Announces Results of U.S. Clinical Trials in Adults Following One Dose of Influenza A (H1N1) Vaccine
October 2, 2009
- Updated Advaxis Phase I Survival Data Indicates Long-Term Immune Protection
- RegeneRx's Tβ4 Significantly Improves Functional Recovery in Multiple Sclerosis Animal Model
- Additional Analysis Confirms Significant Symptomatic Benefit of Droxidopa in Treatment of Neurogenic Orthostatic Hypotension
- LifeCycle Pharma Announces Positive Results from a 12 Month Extension Phase of the Phase 2 Clinical Study of LCP-Tacro Once Daily in Stable Liver Transplant Patients
- Ardea Biosciences to Present Results from a Phase 2a Study of RDEA594 at the 2009 ACR/ARHP Annual Scientific Meeting
- ImmunoCellular Therapeutics' Antibody Shows Promise in Detecting Pancreatic and Lung Cancer in Serum Test
- Dapagliflozin Study Demonstrated Significantly Improved Glycemic Control and Weight Reduction in Type 2 Diabetes Patients Inadequately Controlled with Metformin
- AFRESA Phase 3 Data Show Sustained Glycemic Control, Normal Lung Function in Patients over Four Years of Treatment
- Compelling new data on Novartis' oral MS therapy
- Immutep Announces Final Results In Advanced Renal Cell Carcinoma
- KYTHERA Biopharmaceuticals Presents Positive Data From Two Phase 2 Studies With ATX-101
- Amicus Therapeutics Announces Preliminary Results of Phase 2 Study with Plicera for Gaucher Disease
- Video: New Analysis Supports Tolerability of Lexiscan (regadenoson) Injection for Pharmacologic Myocardial Perfusion Imaging Studies
- Array BioPharma to Present Clinical Results on Diabetes Drug at European Diabetes Meeting
- Intercept Pharmaceuticals' FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
October 3, 2009
- Newly Published Phase III Data Show Novartis Drug Sandostatin LAR Depot Reduced Risk of Disease Progression by 66% in Advanced NET Patients
- OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer; Study Paves Way for Potential Registration Trial as Radiation Sensitizer
- KYTHERA Biopharmaceuticals Announces Presentation of Phase 2 Data on Novel Fat Reduction Drug at ASDS Meeting
- Ulcerative Colitis Treatment Reduces Need for Surgery by Almost Half
- InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting
- Orexigen Therapeutics Phase 2b Trial for Empatic Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus Comparators in Obese Patients
- InteKrin Therapeutics Presents Positive Long Term INT131 Preclinical Cardiovascular Safety Data at the 45th Annual European Association for the Study of Diabetes Meeting
October 4, 2009
- Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cancer
- Superior Efficacy-dose Ratio for Lantus Over detemir
- AEterna Zentaris: Thorough QT Trial with Cetrorelix in Benign Prostatic Hyperplasia Meets Primary Endpoint
October 5, 2009
- SAGE launches "Genes & Cancer"
- Promising Clinical Data with RegeneRx's Tβ4 Drug Candidates Presented on Second Day of Thymosin Meeting
- Transdel Pharmaceuticals to Host Conference Call and Webcast on Tuesday, October 6, 2009 to Announce Top-Line Phase 3 Study Results for Lead Topical Pain Drug Ketotransdel(R)
- Two Phase III Studies of Lucentis Show Early and Sustained Improvement in Vision in Patients with Retinal Vein Occlusion
- Study Finds That Onglyza (saxagliptin) When Added To Metformin Was Non-Inferior To JANUVIA (SITAGLIPTIN) When Added To Metformin In Reducing Hemoglobin (HbA1c) In Adults With Type 2 Diabetes Mellitus
- Positive Phase II Results for GSK1838262 (XP13512) Reported for Subjects with Post-Herpetic Neuralgia and a History of Inadequate Response to Gabapentin
- Depomed, Inc. Announces Positive Top-Line Results from Phase 3 Clinical Trial of DM-1796 in Postherpetic Neuralgia
- Avila Presents Preclinical Data on its Novel, Orally-Available, Pan-Genotype Protease Inhibitor, AVL-181, Demonstrating Protein Silencing of Hepatitis C Virus
- Long-Term Data from Landmark Phase 3 Safety and Nutritional Study Evaluating Alnara Pharmaceuticals' Liprotamase in Patients with CF to be Presented at 2009 North American Cystic Fibrosis Conference
- Nymox Announces New Pooled Analysis Confirms 12 Month Benefit of NX-1207 Treatment for BPH
- Cocaine Vaccine Shows Promise for Treating Addiction
- ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
- Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
- Molecular Insight Pharmaceuticals Presents Azedra Efficacy Data in Neuroendocrine Tumors
October 6, 2009
- Immutep Announces New Interim Results In Phase I/II Chemoimmunotherapy Trial In Breast Cancer
- Antidepressant Use During Pregnancy Associated With Some Adverse Outcomes in Newborns
- AVANIR to Present Pivotal Zenvia Phase III Data at American Neurological Association and World Congress on Controversies in Neurology Annual Meetings
- Merz Pharmaceuticals Announces Phase III Data for NT 201 in Post-stroke Upper Limb Spasticity
- Topical NSAID Shows Positive Result in Phase III trial
- Nature Medicine celebrates 15th anniversary with expanded content and editorial team
- TOPICA Announces Positive Phase 2 Clinical Results for Luliconazole, a Potent Topical Antifungal
October 7, 2009
- IDEA updates on Diractin (ketoprofen in TransfersomeR gel) status
- Synexus set to target cancer vaccine trials
- Vical's TransVax CMV Vaccine Elicits Long-Term Immune Responses in Phase 2 Trial
- Repros Reports Androxal Restores Normal Sperm Counts While Increasing Testosterone Levels in Hypogonadal Men
- Early Treatment With Glatiramer Acetate Reduces Risk Of Progressing To ?Full-Blown? Multiple Sclerois By Almost Half (PreCISe study)
- Transdel Pharmaceuticals Announces Positive Phase 3 Study Results for Lead Topical Pain Drug Ketotransdel
- Data From a Head-to-Head Crossover Study Evaluating FOSRENOL and Sevelamer Published Today
October 8, 2009
- MacuCLEAR and Mystic Successfully Complete Phase Ib Clinical Trial for Macular Degeneration
- Antisoma plc (UK) - Antisoma to amend ACCEDE phase III study of AS1413
- Short Strand Of RNA May Help Predict Survival And Response To Treatment For Patients With Liver Cancer
- Panenza and Humenza Influenza A(H1N1) Vaccines Demonstrate Robust Immune Response After One Dose
- Advaxis Live Listeria Vaccine Induces Epitope Spreading
- Cold Spring Publishing Announces the Launch of a New Oncology Publication: The Journal of the Advanced Practitioner in Oncology
- Journal of Asthma & Allergy Educators New Journal Launched By SAGE and the Association Of Asthma Educators
October 9, 2009
- Angiochem to Present New Clinical Data for ANG1005 in Brain Cancers at Society for Neuroscience Meeting
- AVANIR Pharmaceuticals Presents Zenvia Phase III Results in Multiple Sclerosis Patient Population at Controversies in Neurology Congress
- Results Published In Journal of Cystic Fibrosis Confirm Creon (pancrelipase) Delayed-Release Capsules Improves Fat Absorption in Patients With Cystic Fibrosis
October 12, 2009
- Depomed Reports Results From Two Phase 3 Clinical Trials Evaluating Non-Hormonal Therapy for Menopausal Hot Flashes
- Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH)
- Topline Results from Phase 2 Clinical Trial of Oral NKTR-118 Presented at 20th American Academy of Pain Management Annual Clinical Meeting (AAPM) in Phoenix
- NOXXON Pharma AG Announces Excellent Preliminary Phase I Trial Results for Spiegelmer NOX-E36 ? Good Safety and Pharmacodynamic Profile and Additional Good Subcutaneous Bioavailability
- Synta Pharmaceuticals Announces Updated Elesclomol SYMMETRY Data Presented at Melanoma XIII
- Avodart (dutasteride) in combination with tamsulosin shows benefits for men with benign prostatic hyperplasia (enlarged prostate)
- SLACK Incorporated Appoints Simon VP of Meeting and Exhibit Services
- Clinical Remissions in Three Otherwise Intractable Cancers Signal the Progress of Targeted Genetic Medicine
October 13, 2009
- New Study Assesses Skin Hydration And Epidermal Function Of 2.5% And 5% Benzoyl Peroxide-Clindamycin Combinations
- Alkermes Announces Positive Results From Two Clinical Trials of ALKS 33
- GSK?s Avodart / tamsulosin combination showed benefits for men with prostate enlargement
- Argos Therapeutics to Present Positive Immune Response and Viral Load Data for Arcelis HIV Program at the AIDS Vaccine 2009 Conference
- Metabolex Announces Positive Phase 1 Clinical Trial Results of MBX-2982
- AVANIR Pharmaceuticals Presents Detailed Zenvia Confirmatory Phase III Results in Late-Breaker Session at American Neurological Association Meeting
October 14, 2009
- Ziopharm Announces Positive Palifosfamide Sarcoma Randomized Phase II Interim Data: Trial Enrollment Stopped Early
- Advanced U.S. Clinical Trial Confirms Single-Agent Efficacy of Rexin-G in Metastatic Pancreas Cancer: All Endpoints Achieved
- New Data Showed Type 2 Diabetes Patients Experienced Greater Blood Sugar Reductions when Treated with ACTOplus met (pioglitazone HCl and metformin HCl) as Initial Therapy Compared to Either Component Alone
October 15, 2009
- Surgeons Discover That Common Anti-Clotting Drug May Cause Problems for Some Trauma Patients
- NanoBio's Nanoemulsion Kills Drug-Resistant Bacteria Found in Cystic Fibrosis Patients
- Human Genome Sciences to Host November 2nd Conference Call to Discuss Top-Line Results from Second Phase 3 Trial of Benlysta (Belimumab) in Systemic Lupus Erythematosus
- KaloBios' KB001 Antibody Shows Encouraging Safety and Activity in New Approach to Fighting Pseudomonas Infection in Cystic Fibrosis Patients
- Inspire Announces Presentation at the North American Cystic Fibrosis Conference and Provides Enrollment Update for Phase 3 Cystic Fibrosis Trial
- Protalix BioTherapeutics Announces Positive Top-line Results from its Phase III Clinical Trial of UPLYSO for the Treatment of Gaucher Disease
- Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program
- CREON (pancrelipase) Delayed-Release Capsules Improves Absorption of Fat in Young Children With Cystic Fibrosis
October 16, 2009
- Interim analysis of an ongoing phase II study with nicotine vaccine shows primary endpoint not achieved
- Study Results Suggest Oral Salmon Calcitonin Using Eligen Drug Delivery Technology May Reduce Cartilage and Bone Degradation in Osteoarthritis
- Targacept Presents Data from Highly Successful Phase 2b Trial of TC-5214 as Augmentation Treatment for Major Depressive Disorder
October 18, 2009
- Forest Laboratories and Cypress Bioscience Announce Study Shows Patients Treated with Savella Experience Improvements in Pain and Physical Function
- Uloric (febuxostat) Demonstrated Efficacy for Management of Hyperuricemia in Patients with Gout
- UCB's Cimzia (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis
October 19, 2009
- Angiochem's ANG1005 Demonstrates Safety and Efficacy in Phase 1/2 Brain Cancer Studies
- Ardea Biosciences Announces Additional Positive Results from a Phase 2a Study of RDEA594 at the 2009 ACR/ARHP Annual Scientific Meeting
- BENZEFOAM Emollient Foam Demonstrates Significant Reduction in Propionibacterium acnes in Study Presented at the Fall Clinical Dermatology Conference
- Alnara Pharmaceuticals' Liprotamase Demonstrates Long-Term Safety & Maintenance of Nutritional Status in Patients with CF; Results of Landmark Phase 3 Safety Study Reported
- Rexahn Reports Positive Top-line Phase IIa Data for Serdaxin in Patients with Major Depressive Disorder (MDD)
- Study Shows Good Response for New Drug in Patients with Rheumatoid Arthritis
- Transave Completes Successful Phase II Clinical Program for Arikace in the Treatment of Pseudomonas Lung Infections
- Trubion Pharmaceuticals, Inc. Reports Positive Data from Phase 2b Re-treatment Study of TRU-015
- Northern Light Adds 4,000 Bio-Pharma, Health Sciences and General Business News and Journal Sources from EBSCO Publishing
- Schering-Plough Highlights Boceprevir, Narlaprevir (SCH 900518) and Pegintron Data at the American Association for the Study of Liver Diseases (AASLD) 2009 Annual Meeting
- Oxford Biomedica Announces Update On Prosavin Phase I/Ii Trial In Parkinson's Disease And Publication Of Preclinical Results
October 20, 2009
- Human Genome Sciences and GlaxoSmithKline Announce Full Presentation at ACR of Positive Phase 3 Study Results for Benlysta in Systemic Lupus Erythematosus
- BioSante Pharmaceuticals Reports Positive LibiGel Safety Data in Phase III Program - Oct 20, 2009
- Data Analysis Reinforces the Safety Profile of Levemir
- New Study Assesses Skin Hydration and Epidermal Function of 2.5% and 5% Benzoyl Peroxide-Clindamycin Combinations
- Updated Data from Randomized Controlled Phase II Study Evaluating Oral Apremilast in Psoriatic Arthritis Demonstrates Sustained Response at Six Months
- ORENCIA (abatacept) Demonstrated Sustained Clinical Response in a Study of Adult Patients with Moderate to Severe Early Rheumatoid Arthritis (Less Than Two Years Duration)
- Calistoga Pharmaceuticals Presents Interim Clinical Efficacy Results from Ongoing Clinical Trial of CAL-101 at the International Workshop on Chronic Lymphocytic Leukemia
- Idera Pharmaceuticals Presents Preclinical Data at ACR/ARHP 2009 Annual Meeting on IMO-3100, a Toll-Like Receptor Antagonist, in Combination with Enbrel in Arthritis Model
- Study Results: Novel Oral PTH Formulation Using Emisphere's Eligen Technology Showed Potential Therapeutical Advantages to Available Injectable PTH in Postmenopausal Osteoporotic Women
October 21, 2009
- New FDA Web Page Lists Disposal Instructions for Select Medicines
- "Monoclonal antibody BT-061 shows efficacy in patients with rheumatoid arthritis"
October 22, 2009
- Aerie Pharmaceuticals' ROCK Inhibitor, AR-12286, Demonstrates Positive Results in Glaucoma Patients in a Phase 2a Study
- CombinatoRx'S Synavive (CRx-102) Maintains Efficacy Throughout 12 Month Phase 2 Knee OA Extension Trial
- Argos Therapeutics Presents Positive Phase 2 Viral Load and Immune Response Data for Arcelis HIV Program at the AIDS Vaccine 2009 Conference
- Teva Comments on Positive Results of Phase III Trial in MediWound's Debrase
- AcelRx Announces Positive Results from a Phase 2 Study of ARX-03, a Sufentanil/Triazolam NanoTab for Procedural Sedation, Anxiolysis & Analgesia
- Medtronic Highlights Positive ONSET Pediatric Diabetes Trial Results
- Aeolus Drug Protects the Gastrointestinal Tract in Acute Radiation Syndrome Studies Sponsored by the National Institutes of Health's National Institute for Allergy and Infectious Diseases
October 23, 2009
- Halozyme Study Results Show Faster Insulin Absorption when Administered in Combination with a Wide Range of PH20 Enzyme Concentrations
- Lubris, Biomodels Report on Potential New Therapy for Osteoarthritis
- New Data Presented at ACR Meeting Demonstrates Colcrys (Colchicine, USP) Significantly Reduces Pain of Acute Gout Flare Within 24 Hours With Side Effects Comparable to Placebo
- New Simponi Data Show Inhibition of Joint Damage in Patients With Rheumatoid Arthritis and Psoriatic Arthritis
- Newly Published Clinical Data Shows Caldolor (Ibuprofen) Injection Reduces Opioid Use While Improving Pain Relief in Post-Operative Patients
- Patients Taking Vimovo Showed a Decrease in Incidence of NSAID-Associated Ulcers
- Detailed Results from RV 144 HIV Vaccine Trial Published Today in The New England Journal of Medicine and Presented at the AIDS Vaccine 2009 Conference Provide Insight for Future Research
- NicOx presents 26 week naproxcinod efficacy data at American College of Rheumatology
- Novartis drug Tasigna meets primary endpoint in pivotal trial against Gleevec as first-line treatment in chronic myeloid leukemia patients
- New Phase II data show ACZ885 gave better pain relief and flare prevention for patients with chronic gout than an injectable corticosteroid
- TransMolecular's 131I-TM601 Shown to Improve Survival in Recurrent Malignant Glioma
- Exelixis and Bristol-Myers Squibb Report New Phase 2 Data for XL184 in Patients With the Most Common and Aggressive Form of Brain Cancer
- KYTHERA Biopharmaceuticals Announces Two Data Presentations on Its Novel Fat Reduction Drug at ASPS Meeting
- TargeGen Announces Successful Completion of Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients
- Research Into Cancer During Pregnancy: Treating Pregnant Women With Chemotherapy has no Detrimental Effect on the Foetus
- Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Patients With Non-Responsive Thyroid Cancer
- Shire Announces New Data on Pharmacokinetics of Vyvanse
- Interim Clinical Trial Results Show MedImmune's H1N1 Vaccine Has Similar Safety Profile as Seasonal Vaccine in Eligible Children and Adults
October 24, 2009
- Landmark Study Shows Substantial Improvement in Survival and Renal Recovery for Acute Kidney Injury Patients Treated With CRRT
- New Study Results Show That Patients Have Higher Treatment Satisfaction With Liraglutide Compared to Exenatide
- Bleeding is Rare in IVF Patients Who Become Pregnant When Treated with a Combination of Vaginal Progesterone Gel and Estrogen
- The risk of venous thromboembolism for drospirenone containing oral contraceptives is comparable to the risk of other oral contraceptives available on the market
- Orexigen Therapeutics Presents New Data Showing Weight Loss with Contrave Significantly Improves Important Markers of Cardiometabolic Risk
October 25, 2009
- New Animal Study Featured in the Journal of Cellular Biochemistry Supports Rexahn's Archexin as Potent Inhibitor of Human Cancer Cell Growth
- Study Demonstrates Livalo Is an Efficacious Treatment for Achieving Lipid Goals
October 26, 2009
- SAGE Launches "Therapeutic Advances in Musculoskeletal Disease"
- NPS Reports Two Teduglutide Abstracts Accepted for Presentation at American College of Gastroenterology Annual Scientific Meeting
- Positive Data from Two Investigator-Initiated Studies with Santarus' ZEGERID to Be Presented At ACG
- "Journal of Primary Care & Community Health" New quarterly journal for 2010
- Data Presented On Oncophage Cancer Vaccine In Recurrent Glioma At Sno 2009
- Vical's Vaxfectin Adjuvant Drives 200-Fold Increase in Antibody Responses With Sanofi-Pasteur Fluzone Seasonal Influenza Vaccine
- Theratechnologies: International Workshop on Adverse Drug Reactions and Co-morbidities in HIV
- Halsa Pharmaceuticals Announces ZAG Demonstrates Weight Loss, Rise in Temperature and Reduction of Diabetes Symptoms in Preclinical Studies at Obesity 2009 Annual Scientific Meeting
- Data Demonstrate That GATTEX(Teduglutide) Improves Lean Body Mass, Mineral Composition and Electrolyte Levels in Patients with Parenteral Nutrition Dependent Short Bowel Syndrome
- ImmunoCellular Therapeutics to Present Today Data From Phase I Clinical Trial of ICT-107 at Annual Meeting of Congress of Neurological Surgeons
- New Study Results Analyzed the Use of Kapidex (dexlansoprazole) for Nighttime Heartburn in Adults with Non-Erosive GERD
- Horizon Therapeutics Presents Phase 3 Study Results Identifying Risk Factors for Ulcer Development Among NSAID Users
- Inhibitex Announces Data Presentation at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
- Salix Pharmaceuticals Previews American College of Gastroenterology 2009 Annual Scientific Meeting
- New Data Presented From WELCOME Trial Show Positive Impact of Cimzia (certolizumab pegol) on Hospitalizations and Surgeries in Patients With Prior Infliximab Failure
- Creon (pancrelipase) Delayed-Release Capsules Improves Digestive Outcomes In Adults With Chronic Pancreatitis
- Shire Presents Results of Five Lialda (mesalamine) Analyses at ACG 2009 Annual Scientific Meeting
October 27, 2009
- Icagen Reports Top-line Results of Phase IIa Study of Senicapoc in Exercise-Induced Asthma
- New Data From Arena Pharmaceuticals' Pivotal BLOSSOM Trial of Lorcaserin Demonstrate Improvements in Patients' Body Composition, Cardiovascular Risk Factors and Quality of Life
- Orexigen Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
- Phase 2 Data From Oral NKTR-118 Presented at American College of Gastroenterology in San Diego
- Isotechnika Pharma Announces Voclosporin Presentations at American Academy of Ophthalmology
- Results of Phase I Study Show Novel, Investigational PA65020 Compound Significantly Decreased Risk of Upper GI Damage in Healthy Adults
- PolyMedix Completes Successful Phase 1B Clinical Study of Heparin Antagonist PMX-60056
- ImmunoCellular Therapeutics Presents Data from Phase I Trial of ICT-107 Demonstrating Significant Increase in Tumor-Free Progression in Patients with Brain Cancer
- Logical Therapeutics Announces Positive Results of LT-NS001 vs. Naproxen Clinical Study
October 28, 2009
- Interim Results from Study 107 Highlight the Potential Role of Telaprevir-Based Regimens in HCV Patients Who Failed Prior Treatment
- New Data Supports Pharmacoeconomic Benefits of Ceplene
- Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis
- Study demonstrates effectiveness of once-daily dose of Asacol for ulcerative colitis
- Updated European guidelines highlight benefits of Rasilez, the only approved direct renin inhibitor, in treating high blood pressure
- SCYNEXIS to Present HCV Data on Novel Cyclophilin Inhibitor SCY-635 at AASLD Annual Meeting
- Forest Laboratories, Inc. and Gedeon Richter Announce Positive Results from a Phase IIb Study of Cariprazine for the Treatment of Schizophrenia
- Difficult-to-Treat Patient Populations Respond Positively to Hepatitis C Treatment
October 29, 2009
- Genta Announces Top-Line Results of AGENDA Phase 3 Trial of Genasense in Patients with Advanced Melanoma
- Celldex Therapeutics Presents Positive Clinical Data from Phase 1 Studies of Antibody-Based Cancer Vaccine Candidate, CDX-1307
- Genta Incorporated Announces Conference Call to Review Top-Line Results of AGENDA Phase 3 Trial of Genasense in Patients with Advanced Melanoma
- Subset Data from Two Randomized Phase 3 Trials Show TYSABRI Significantly Reduces Rates of Hospitalization in Patients with Moderate-to-Severe Crohn's Disease
October 30, 2009
- YM Biosciences Reports Additional Results From Nimotuzumab Phase III Study In Children With Glioma Presented By Oncoscience Ag
- Data Presented on Cempra Pharmaceutical's CEM-101 at the Infectious Diseases Society of America Annual Meeting Reinforces Potency and Coverage Against Multidrug-Resistant S. Pneumoniae Isolates
- Presentations of Cempra Pharmaceutical's CEM-102 (fusidic acid) at the Infectious Diseases Society of America Annual Meeting Highlight Properties That Make It an Excellent Anti-MRSA Candidate
- Idenix Pharmaceuticals Presents Data on IDX184 for the Treatment of Hepatitis C Virus (HCV)
- Bayer HealthCare Presents Florbetaben Phase II Study Results at World Congress of Neurology
- A Decade Later, Lifestyle Changes Or Metformin Still Lower Type 2 Diabetes Risk
- Inappropriate Initial Antibiotic Treatment May Extend Stays for Patients with Healthcare-Associated Skin Infections
- Affymax and Takeda Announce Preliminary Phase 2 Data Demonstrated That Hematide Increased Hemoglobin in Dialysis Patients
